Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026

Summary by AI BETAClose X

Novo Nordisk announced positive results from a sub-population analysis of the STEP UP trial, demonstrating that Wegovy® (semaglutide 7.2 and 2.4 mg) significantly reduced liver fat in adults with obesity and excess liver fat. After 72 weeks, 88.5% of participants with baseline liver fat above 5% achieved normal levels below 5%, and overall liver fat decreased from a mean of 8.8% to 3.1%. This analysis, presented at EASD 2026, suggests Wegovy® may help address liver disease early in individuals with obesity, potentially mitigating long-term health risks.

Disclaimer*

UK 100

Latest directors dealings